Emotional eating in patients attending a specialist obesity treatment service.


Journal

Appetite
ISSN: 1095-8304
Titre abrégé: Appetite
Pays: England
ID NLM: 8006808

Informations de publication

Date de publication:
01 08 2020
Historique:
received: 22 08 2019
revised: 06 04 2020
accepted: 07 04 2020
pubmed: 14 4 2020
medline: 25 6 2021
entrez: 14 4 2020
Statut: ppublish

Résumé

The prevalence of emotional eating (EE) has increased in the general population over past decades. There is limited information on how common EE is among people seeking obesity treatment. We aimed to estimate the proportion of people with EE, and strength of associations between a predefined set of factors and EE in people referred for obesity treatment. Cross-sectional study recruiting 387 adults from a hospital obesity service. "Emotional eating" was defined as Emotional Eating Scale (EES) score ≥25. Strength of associations were estimated by boot-strapped quantile regression analysis. Results are presented as quantile difference (QD) of EES scores at the 25th, 50th or 75th quantile, and 95% confidence intervals (95%CI). The study population consisted of 71% women, with a median age of 52 years (interquartile range [IQR]: 42, 61), and a median body mass index of 42 kg/m Emotional eating affected more than half of people referred for obesity treatment. Age, sex, use of GLP-1 agonists, history of sleeve gastrectomy and recent bariatric surgery had the strongest associations with EE. These findings allow hypothesis generation about the underlying physiological mechanisms behind emotional eating for investigation in future research.

Identifiants

pubmed: 32283188
pii: S0195-6663(19)31074-8
doi: 10.1016/j.appet.2020.104708
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104708

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest PS has participated in Advisory Boards for Novo Nordisk and received payment for a lecture from Novo Nordisk unrelated to this work. The other authors declare no conflicts of interest.

Auteurs

Lisa Wong (L)

Department of Medicine (Austin), University of Melbourne, Melbourne, Victoria, Australia.

Lauren Stammers (L)

Department of Medicine (Austin), University of Melbourne, Melbourne, Victoria, Australia.

Leonid Churilov (L)

Department of Medicine (Austin), University of Melbourne, Melbourne, Victoria, Australia.

Sarah Price (S)

Department of Medicine (Austin), University of Melbourne, Melbourne, Victoria, Australia.

Elif Ekinci (E)

Department of Medicine (Austin), University of Melbourne, Melbourne, Victoria, Australia; Dept of Endocrinology, Austin Health, Melbourne, Victoria, Australia.

Priya Sumithran (P)

Department of Medicine (Austin), University of Melbourne, Melbourne, Victoria, Australia; Dept of Endocrinology, Austin Health, Melbourne, Victoria, Australia. Electronic address: priyas@unimelb.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH